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SUMMARY

How cancer cells shift metabolism to aerobic glycolysis is largely unknown. Here, we show that deficiency of a/b-hydrolase domain-containing 5
(Abhd5), an intracellular lipolytic activator that is
also known as comparative gene identification 58
(CGI-58), promotes this metabolic shift and enhances
malignancies of colorectal carcinomas (CRCs).
Silencing of Abhd5 in normal fibroblasts induces malignant transformation. Intestine-specific knockout of
Abhd5 in ApcMin/+ mice robustly increases tumorigenesis and malignant transformation of adenomatous polyps. In colon cancer cells, Abhd5 deficiency
induces epithelial-mesenchymal transition by suppressing the AMPKa-p53 pathway, which is attributable to increased aerobic glycolysis. In human CRCs,
Abhd5 expression falls substantially and correlates
negatively with malignant features. Our findings link
Abhd5 to CRC pathogenesis and suggest that cancer
cells develop aerobic glycolysis by suppressing
Abhd5-mediated intracellular lipolysis.
INTRODUCTION
Cancer is a leading cause of death. The etiology of cancer is
attributed to both genetic and environmental factors. Many
oncogenes and tumor-suppressor genes have been identified
(Vogelstein and Kinzler, 2004). Interestingly, the products of
these genes are often positioned at the critical nodes of important metabolic networks, and their activities are hyperresponsive
to metabolic perturbations (Jones and Thompson, 2009). For
example, during metabolic stress, the AMP-activated protein kinase (AMPK) activates the tumor suppressor p53 (Feng et al.,
2005), and the mammalian target of rapamycin (mTOR) seems
to modulate this activation (Lee et al., 2007). Both AMPK and

mTOR play critical roles in energy sensing (Hardie, 2007; Tokunaga et al., 2004) and tumorigenesis (Faubert et al., 2013;
Vogt, 2001). mTOR mediates the growth signals originated
from a well-known master regulator of cell metabolism, phosphatidylinositol 3 kinase (PI3K). The PI3K/Akt/mTOR pathway
critically controls protein translation via activation of p70 S6
kinase (S6K) and eukaryotic initiation factor 4E (Vogt, 2001).
Additionally, inborn or acquired mutations of several metabolic
enzymes are associated with the development and progression
of several types of cancer, highlighting important roles of altered
cell metabolism in cancer etiology (Das et al., 2011; DeBerardinis
and Thompson, 2012; Frezza et al., 2011; Gao et al., 2012; Lyssiotis and Cantley, 2012; Mullen et al., 2012; Nomura et al., 2010;
Yang et al., 2012).
In mammalian cells, glucose, fatty acids, and amino acids
such as glutamine are major energy sources. A hallmark of
cancer cells is the glycolytic breakdown of glucose for ATP production in the presence of ample oxygen to fuel mitochondrial
oxidative phosphorylation. This aerobic glycolysis is known as
the ‘‘Warburg effect’’ (Warburg, 1956). Although the Warburg effect has been demonstrated to contribute critically to cancer
pathogenesis, it is largely unknown how cancer cells shift their
energy metabolism to aerobic glycolysis. Malignant tumors
such as hepatocellular carcinoma and colorectal carcinoma
(CRC) often show increased intracellular lipid droplet (LD) deposition (Bozza and Viola, 2010; Straub et al., 2008), implying an
aberrant lipid metabolism. Cellular fat homeostasis is controlled
by balanced biosynthesis and utilization. Mobilization of stored
fat in adipocytes for use as energy is called lipolysis. Cytosolic
fat lipolysis requires at least three different enzymes: (1) adipose
triglyceride lipase (ATGL) that catalyzes the first step of lipolysis,
converting triglycerides (TGs) to diacylglycerols (DAGs) (Zimmermann et al., 2004); (2) hormone sensitive lipase (HSL), mainly
responsible for the conversion of DAGs to monoacylglycerols
(MAGs); and (3) monoacylglycerol lipase (MAGL) that hydrolyzes
MAGs to release the last fatty acyl chain from the glycerol backbone. Recently, lipid-specific macroautophagy (lipophagy) was
shown to clear some cytosolic LDs by delivering LD-associated

1798 Cell Reports 9, 1798–1811, December 11, 2014 ª2014 The Authors

fat to lysosomes for degradation by acidic lipases (Singh et al.,
2009). It is likely that these intracellular pathways crosstalk
with each other to ultimately determine the level of fat utilization
in a cell. While increased de novo lipid biosynthesis has long
been known to play an important role in cancer growth (Menendez and Lupu, 2007), the role of disrupted fat utilization in cancer
development and progression has just begun to be explored. It
was shown that MAGL deficiency inhibits cancer pathogenesis
(Nomura et al., 2010). Recently, ATGL deficiency was shown to
protect against cancer-associated cachexia (Das et al., 2011).
Although the role of lipophagy in cancer remains unknown, macroautophagy is known to influence the pathogenesis of cancer
(Levine and Kroemer, 2008; White and DiPaola, 2009). Nonetheless, it is currently unclear whether defective fat utilization plays a
part in shifting a cancer cell’s metabolism to aerobic glycolysis.
ATGL requires a coactivator, comparative gene identification58 (CGI-58), to achieve full TG hydrolase activity (Lass et al.,
2006). CGI-58 is also known as a/b hydrolase domain-containing
protein-5 (abhd5). Mutations in human abhd5 cause ChanarinDorfman syndrome (Chanarin et al., 1975; Dorfman et al.,
1974), a rare autosomal-recessive genetic disease characterized
by TG-rich LD accumulation in almost all tissues but fat. Mutations in human ATGL also cause a neutral lipid storage disease
(Fischer et al., 2007). Despite this similarity, obvious phenotypic
differences exist between ATGL and Abhd5 mutations. For
example, patients with Abhd5 mutations display thickened dry
skin (ichthyosis), but this is absent in patients with ATGL mutations (Fischer et al., 2007; Igal et al., 1997). Mice lacking
Abhd5 die neonatally (Radner et al., 2010), but mice lacking
ATGL are viable (Haemmerle et al., 2006). Liver-specific Abhd5
knockout mice develop hepatic steatohepatitis and fibrosis
(Guo et al., 2013), while liver-specific ATGL knockout mice
display only simple hepatic steatosis (Wu et al., 2011). These
observations indicate that Abhd5 must have functions beyond
activating ATGL.
We have previously shown that antisense oligonucleotide
(ASO)-mediated knockdown (KD) of Abhd5 in adult mice promotes glucose disposal while inhibiting fat utilization (Brown
et al., 2010). Whole-body ATGL knockout mice also show
improved glucose tolerance (Haemmerle et al., 2006). These
observations raised an intriguing question in cancer metabolism:
Is defective fat hydrolysis a cause of aggravated glucose uptake
commonly seen in cancer cells? In the Catalogue of Somatic
Mutations in Cancer (COSMIC) database, the loss of gene
copy number is frequent and the loss of heterozygosity (LOH)
is present for the Abhd5 gene in several human cancer types,
including those of large intestine origin. These animal and human
data led us to hypothesize that Abhd5 may be a potential molecular switch of a cancer cell’s fuel selection. Cancer cells may
choose to downregulate Abhd5 to inhibit fat utilization, thereby
enhancing their aerobic glycolysis. To test this hypothesis, in
this study, we examined the role of Abhd5 in the development
and progression of CRCs, the third leading cause of cancer
deaths in the United States (Jemal et al., 2010). We demonstrated that Abhd5 functions as a colorectal tumor suppressor.
It suppresses colorectal tumorigenesis and malignant transformation by inhibiting aerobic glycolysis and epithelial-mesenchymal transition (EMT), a major hallmark of tumor invasion

and metastasis (Hanahan and Weinberg, 2011). At the cellsignaling level, Abhd5 acts as an activator of AMPK and a negative regulator of the PI3K/Akt/mTOR/p53 pathway to inhibit CRC
growth and invasion.
RESULTS
Abhd5 KD in Colorectal Cancer Cells Promotes Invasive
Capacity via Inducing Epithelial-Mesenchymal
Transition
To examine whether Abhd5 has any relation to cancer biology,
we first knocked down Abhd5 expression in HCT116 human colon cancer cell line. Lentiviral small hairpin RNA (shRNA)-mediated KD of Abhd5 caused decreased apoptosis but had little
effect on proliferation (Figures S1A–S1C). Strikingly, Abhd5-KD
cells acquired fibroblast-like morphology and were loosely scattered (Figure 1A). The highly scattered cells were significantly
increased in Abhd5-KD cells. Transwell Matrigel assays demonstrated that Abhd5-KD cells became more invasive than control
cells, as evidenced by increased cell migration (Figure 1B).
These findings imply that Abhd5-KD cells may have undergone
an EMT (Hanahan and Weinberg, 2011). We then measured
expression levels of EMT markers. As expected, the protein level
of E-cadherin, an epithelial marker, decreased while that of a
mesenchymal marker, Snail, increased in Abhd5-KD cells (Figure 1C). To rule out the potential off-target effects of the shRNA,
we used two additional shRNAs of different sequences to silence
Abhd5 expression in HCT116 cells and obtained identical results
(Figures S1D and S1E). In addition, we silenced Abhd5 expression in another human colon cancer cell line SW620. Similar results were observed (Figure S1F).
To further confirm the role of Abhd5 in regulating EMT and
migration capacity of colorectal cancer cells, we overexpressed
Abhd5 in a highly aggressive SW480 human colon cancer cell
line whose endogenous Abhd5 protein level is low relative to
many other colon cancer cell lines (Figure 1D). Abhd5 overexpression dramatically attenuated the migration capacity of
SW480 cells, suggesting reduced invasiveness (Figure 1E). It
also upregulated E-cadherin and downregulated Snail expression (Figure 1F), consistent with a mesenchymal-epithelial transition, a biological process opposite to EMT and indicative of
reduced mesenchymal phenotypes.
Given the critical role of EMT in tumor metastasis, we examined the ectopic growth capacity of Abhd5-KD cells in vivo.
Nude mice injected with Abhd5-KD HCT116 cells showed a dramatic increase of tumor lesions in the lung, the primary target
organ of tail vein-injected cancer cells (Figure 1G). After fixation,
increased tumor lesions became apparent (Figure 1G, middle).
When lung surface lesions were counted and measured, the
tumor number and size were significantly increased in the KD
group (Figure 1G, left). The tumor lesions derived from Abhd5KD, but not control, HCT116 cells also appeared in other tissues,
including subcutaneous regions, mediastinum, chest wall, and
adrenal gland (Figure S1G). Hematoxylin and eosin (H&E) staining of the pulmonary lesions (Figure 1H) showed that the lesions
from control HCT116 cells exhibited a typical glandular
morphology surrounded by a fibrous layer. The majority of the
pulmonary lesions originated from Abhd5-KD HCT116 cells
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Figure 1. Abhd5 Suppresses EMT and Growth Advantage of CRC Cells
(A) Morphology (crystal violet staining and phase contrast) of HCT116 control and Abhd5-knockdown (KD) cells. One hundred cells in each colony were counted
under microscopy (2003). Ten colonies were counted for each group. Epithelial, cells attached to each other tightly; scattered, cells scattered, but still attached to
others; highly scattered, scattered cells that had no contact with others. *p < 0.01; ***p < 0.0001. Scale bar represents 50 mm.
(B) Transwell assays. Scale bar represents 200 mm.
(C) Western blots of EMT markers.
(D) Western blots of Abhd5 in colon cancer and normal colon epithelial cell lines.
(E) Transwell assays of SW480 cells overexpressing Abhd5. Scale bar represents 200 mm.
(F) Western blots of EMT markers in SW480 cells overexpressing Abhd5.
(G) Lung tumor lesions induced by the tail vein injection of HCT116 cells in nude mice (left, nonfixed organ; right, formalin-fixed organ).
(H) H&E staining of the above lung tumors. Scale bar represents 100 mm.
(I–K) Immunohistochemistry of Ki67, Abhd5, and ADRP in the above lung tumors. Scale bar represents 100 mm.

had a necrotic core. The tumor cells at the edge failed to form
glandular appearance and fibrous layer and were often spread
out to adjacent lung tissues where glandular structures were
occasionally observed. This microscopic appearance indicates
invasive growth of Abhd5-KD cells in the lung. Ki67-positive
staining was frequently seen in the lesions derived from
Abhd5-KD, but not control, HCT116 cells, suggesting a greater
proliferation potential of KD versus control cells (Figure 1I). Immunostaining of Abhd5 demonstrated the loss of Abhd5 expression in the pulmonary tumors originated from Abhd5-KD cells
(Figure 1J). The adjacent lung tissues stained positive because
the antibody also recognizes mouse Abhd5. A hallmark of
Abhd5 loss is the cytosolic accumulation of LDs. As expected,
the pulmonary tumors derived from Abhd5-KD cells accumulated LDs that were stained positive for ADRP (adipose differentiation-related protein), an LD coat protein (Figure 1K). These
findings collectively indicate that Abhd5 KD substantially increases the growth advantage of HCT116 cells.
Abhd5 KD in Normal Cells Induces Malignant
Transformation
To examine whether Abhd5 loss plays a role in malignant transformation of normal cells, we knocked down Abhd5 expression
in FHC human normal colon mucosal cells and BJ human foreskin fibroblasts using lentiviral shRNAs. Transwell assays
showed that Abhd5 KD in FHC cells significantly increased cell
migration (Figure 2A), which was associated with a reduction in
E-cadherin protein (Figure 2B), indicative of EMT. Silencing
Abhd5 in BJ cells (Figure 2C) did not alter cells’ in vitro growth
potential (Figure 2D), but it dramatically enhanced their invasive

capacity across the Matrigel (Figure 2E). Subcutaneous xenograft experiments with BJ cells showed that BALB/c nude
mice injected with Abhd5-KD cells at the thigh developed visible
tumors 2 weeks after cell injection, while the mice injected with
the same amount of control cells showed no tumors at the
same time. Eight weeks after cell injection, the tumors were
dissected out (Figures 2F and 2G). H&E staining of tumor sections revealed a sarcoma-like morphology (Figure 2H). Immunostaining identified abundant human vimentin in the tumor (Figure 2I). Collectively, these data suggest that Abhd5 KD causes
malignant transformation of normal colon mucosal cells and
foreskin fibroblasts.
Intestine-Specific Inactivation of Abhd5 in ApcMin/+Mice
Promotes Tumorigenesis and Malignant Transformation
of Intestinal Adenomatous Polyps
To establish a causal role for Abhd5 loss in CRC pathogenesis
in vivo, we crossed the adenomatous polyposis coli (Apc)Min/+
allele (Su et al., 1992) into the intestine-specific Abhd5 knockout
mice (Xie et al., 2014). Strikingly, selective inactivation of Abhd5
in the intestine of ApcMin/+ male mice (ApcMin/+/Abhd5f/f/Cre+)
caused a significant increase of tumor number and size in both
small intestine and colorectum (Figures 3A–3D). Similar changes
were observed in female mice (data not shown). Unlike humans
carrying Apc mutations, who develop macroscopic tumors
mainly in the colorectum, regular ApcMin/+ mice develop adenomatous polyps mainly in the small intestine, and colorectal
polyps are rare (Su et al., 1992). Interestingly, all Abhd5-deficient
ApcMin/+ mice showed extensive distension of colorectum and
frequent rectal prolapse, which was unprecedented in regular
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Figure 2. Abhd5 Knockdown Induces Malignant Transformation of Normal Colon Mucosal Cells and Foreskin Fibroblasts
(A) Transwell assays of Abhd5-KD and control FHC cells (passage 14). Scale bar represents 200 mm.
(B) Western blots.
(C) Abhd5 knockdown.
(D) Growth curve of normal and Abhd5-KD BJ cells.
(E) Transwell assays. Scale bar represents 200 mm.
(F) Gross appearance of subcutaneous xenografts in BALB/c nude mice 8 weeks after injection of control or Abhd5-KD BJ cells (5 3 104 cells per mouse).
(G) Subcutaneous xenografts dissected from the mice described in (F).
(H) H&E staining of the above subcutaneous xenografts. Scale bar represents 100 mm.
(I) Immunohistochemistry of human vimentin in the above xenografts. Scale bar represents 50 mm.

ApcMin/+ mice at the same age. The average tumor number and
size increased significantly in the colorectum of Abhd5-deficient
ApcMin/+ mice (Figures 3C and 3D). Due to robust increases
in tumor burden, these animals developed severe anemia at
100 days of age, as evidenced by a dramatic decline in red blood
cells and blood hemoglobin (Figure 3E), as well as by increased
spleen size and weight (Figures 3F and 3G). Very impressively, all
of the aforementioned phenotypes were gene-dose dependent.
Besides increased tumor number and size, many tumors
formed in Abhd5-deficient ApcMin/+ mice were highly dysplastic
with cauliflower-like surfaces, profound architectural distortion,
and cytological alterations to a level that was highly uncommon
in human or murine polyps but characteristic of carcinomas,
including the tightly and irregularly arranged tall and columnar
cells, dark stain, atypical glandular proliferation with a back-toback phenomenon and the two glands sharing the same glandular wall, loss or disorder of cell polarity, increased ratios of
cell nucleus to cytoplasm, pleomorphic nuclei with prominent
nucleoli, and activities of mitosis and pathological mitosis (Figures 3A, 3C, 3H, and S2A). There was an increased stromal reaction to the cancer as evidenced by increased expression
of CD31, an angiogenic marker (Figure S2B). We frequently
observed adenocarcinomas in the submucosa and muscularis

propria in the ilea of Abhd5-deficient ApcMin/+ mice (Figure 3H),
a feature of malignancy that was not present in the control
mice of the same age. Even a single Abhd5-null allele significantly enhanced the invasiveness of ApcMin/+ tumors (Figure 3H,
Hetero.). Immunostaining of Abhd5 in the intestinal tumors
revealed that the expression of this single Abhd5 allele was not
inactivated (Figure 3I). Abhd5-deficient tumors showed accumulation of ADRP (Figure S3A), an LD coat protein. Notably, one out
of nine Abhd5-deficient ApcMin/+ males at 100 days had liver
metastases (Figure S3B) from aggressive intestinal tumors that
clearly penetrated the muscle layer (Figure S3C). H&E staining
of the liver tumors often revealed a necrotic core and the glandular structures at the edge that penetrated into the liver tissue
(Figure S3D). The intestinal origin of liver tumors was confirmed
by immunostaining of CK20 (Figure S3E), a marker of intestinal
epithelial cells, as well as CDX-2 (Figure S3F), an intestinal
transcription factor. This evidence from Abhd5 knockout mice
demonstrates that loss of Abhd5 promotes the malignant transformation of benign intestine adenomas.
Loss of Abhd5 Is a Hallmark of CRCs
In the COSMIC database, Abhd5 gene shows the loss of heterozygosity and frequent copy-number variation (mostly loss of
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Figure 3. Intestine-Specific Knockout of Abhd5 Promotes Tumorigenesis and Aggressiveness of Tumors in ApcMin/+ Mice
(A) Macroscopic appearance of tumors in the distal ilia of 100-day-old male mice. Control, ApcMin/+/Abhd5+/+/Cre+; Hetero, ApcMin/+/Abhd5f/+/Cre+; Homo,
ApcMin/+/Abhd5f/f/Cre+.
(B) Statistical analysis of tumor number and size in the entire small intestine.
(C and D) Macroscopic appearance (C) of tumors and statistical analysis of tumor number and size (D) in the colorectum of 100-day-old mice.

(legend continued on next page)
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Figure 4. Loss of Abhd5 Expression Correlates Positively with CRC Development and Progression in Humans
(A) Oil red O staining of the normal colon mucosa and the colon carcinoma from the same patient. Ten patients were examined and similar results obtained. Scale
bar represents 200 mm.
(B and C) Representative immunostaining images (B; scale bar represents 200 mm) and statistical analysis (one-way ANOVA) of expression index (C) of Abhd5 in
colon tissues of different diseases. p < 0.001 between carcinoma and each of other disease stages.
(D) A representative immunostaining image of Abhd5 in a human colon carcinoma and its adjacent normal tissue, showing gradual loss of Abhd5 expression.
Scale bar represents 200 mm.
(E and F) Statistical analysis of Abhd5 expression levels between M0 CRCs (n = 218) and M1 CRCs (n = 34) (E) (Student’s t test) and among CRCs of different
stages (F) (one-way ANOVA). I, n = 18; II, n = 117; III, n = 83; IV, n = 34. *p < 0.01; **p < 0.001; ***p < 0.0001.
(G) Fisher’s exact test of the correlation between Abhd5 expression levels and the risk of recurrence in stage I and II CRC patients (n = 57 in no recurrence; n = 41 in
recurrence; p = 0.004).
(H) Statistical analysis of the correlation between Abhd5 expression levels and the overall survival of CRC patients (stages I and II, n = 105; stage III, n = 71).
p < 0.01 (Kaplan-Meier survival curves).

copy number) in several human cancer types, including cancer
of the large intestine. To further probe the relevance of our cell
and animal findings to human pathophysiology, we analyzed
human CRC samples and patient histories. Since it has been reported that cancer tissues relative to normal tissues of their origins often accumulate more LDs (Accioly et al., 2008; Straub
et al., 2010), we first stained LDs in CRC tissues and their adjacent normal colon tissues from ten patients (eight colon and

two rectal cancer patients) to determine if these previous observations could be recapitulated in our cohort of CRC specimens.
Consistently, all CRC tissues examined displayed increased LDs
(Figure 4A). Next, we immunostained Abhd5 in a tissue chip containing normal colon mucosa and colon specimens of hyperplasia, colitis, adenoma, and carcinoma. Abhd5 expression levels
were substantially decreased in CRCs versus normal and benign
colon pathological alterations, but there were no differences in

(E) Red blood cell counts in 100-day-old mice.
(F and G) Macroscopic appearance (E) of spleens and statistical analysis (F) of spleen-to-body weight ratios in 100-day-old mice.
(H) Representative H&E sections of tumors in the small intestine of control, heterozygous (Hetero.) and homozygous (Homo.) intestine-specific Abhd5 knockout
male mice at 100 days of age. Arrows point to invasive glands. Scale bar represents 100 mm.
(I) Immunohistochemistry of Abhd5 in the tumors described in (H).
Different letters associated with individual bars represent significant statistical differences among the groups (one-way ANOVA; p < 0.0001; n = 9 in all experiments). Scale bar represents 100.

Cell Reports 9, 1798–1811, December 11, 2014 ª2014 The Authors 1803

Figure 5. Abhd5 Deficiency Induces EMT via Inactivating p53
(A) Western blots of total p53 and phosphorylated (P-) p53 levels in HCT116 cells.
(B) Western blots of p53 protein in the cytosol and nucleus of HCT116 cells.
(C) Immunofluorescence staining of p53 in HCT116 cells.
(D) The mRNA levels of p53 target genes in HCT116 cells.
(E) The mRNA levels of p53 target genes in HCT116 cells overexpressing human Abhd5.
(F) Western blots of p53 protein in HCT116 cells overexpressing human Abhd5.
(G) Normalization of E-cadherin and Snail expression by forced expression of p53 in Abhd5-KD HCT116 cells.
(H) Attenuation of increased cell migration by forced expression of p53 in Abhd5-KD HCT116 cells. Scale bar represents 200 mm.
(I) Western blots of Abhd5, p53, E-cadherin, and b-actin in p53-null and parental wild-type control HCT116 cells.

Abhd5 expression among normal colon mucosa, hyperplasia,
and colitis tissues (Figures 4B and 4C). The gradual loss of
Abhd5 expression from normal colon mucosa to paracancerous
tissue to CRC region was often seen in one tissue section (Figure 4D). Since some degree of Abhd5 loss was found in adenomas (Figure 4C), we speculated that loss of Abhd5 might be
associated with the malignant transformation of adenomas, a
critical step of CRC development. We compared Abhd5 expression levels in colorectal adenomas between patients with malignant transformation and those without malignant transformation
(Figure S4A). Consistently, the risk of malignant transformation
was significantly higher in adenomas with extensive loss of
Abhd5 compared to those with less or no Abhd5 loss (Figure S4B). Additionally, in human CRCs, Abhd5 expression levels
were substantially lower in stages M1 and IV than stages M0 and
I–III (Figures 4E and 4F). CRC patients with recurrence after surgical resection exhibited lower Abhd5 expression relative to
those with no recurrence (Figure 4G). CRC patients with lower
Abhd5 expression had poorer prognosis than those with higher
Abhd5 expression (Figure 4H). Our findings from animal and
human studies support that Abhd5 deficiency promotes CRC
progression.
p53 Is Critically Involved in Abhd5 Deficiency-Induced
EMT in Colorectal Cancer Cells
To explore the molecular mechanisms underlying Abhd5 deficiency-induced EMT, we employed cultured cells as a model.
The transcription factor Snail plays an essential role in regulating
EMT. It was shown that Snail directly binds to the promoter region of E-cadherin to inhibit transcription of E-cadherin (Cano
et al., 2000). Many factors are known to suppress Snail expres-

sion, one of which is the potent tumor suppressor p53 (Hahn
et al., 2013; Siemens et al., 2011). We found that total p53 protein
was reduced in Abhd5-KD FHC normal colon mucosal cells (Figure S5A). Similar reduction in total p53 protein was observed in
Abhd5-KD HCT116 cells (Figures 5A and S5B) and Abhd5-KD
SW620 cells (Figure S5C). Interestingly, phosphorylation of p53
was increased at serine 392 and decreased at serine 15, 37,
and 46 of p53 in Abhd5-KD HCT116 cells (Figure 5A). Cell fractionation studies showed that p53 protein was reduced in both
the cytosol and nucleus, with a more dramatic reduction in the
nucleus (Figure 5B). Immunofluorescence staining also revealed
a substantial reduction of p53 protein in the nucleus (Figure 5C).
Consistently, mRNAs for several known target genes of p53 were
significantly reduced (Figure 5D). The opposite was observed
when Abhd5 was overexpressed in HCT116 cells (Figures 5E
and 5F). Abhd5 deficiency does not seem to induce malignant
properties via other classical pathways involved in carcinogenesis, because Abhd5 KD had no effects on protein levels of
c-myc and PTEN and reduced levels of oncogenic Ras protein,
phosphorylated ERK, and b-catenin (Figures S5D and S5E). On
the other hand, forced expression of human p53 in Abhd5-KD
HCT116 cells prevented Abhd5 deficiency from causing EMT
(Figures 5G and 5H). Additionally, when Abhd5 was knocked
down in p53-null HCT116 cells, E-cadherin protein was not
decreased (Figure 5I). Reduced E-cadherin was largely responsible for driving EMT in Abhd5-KD HCT116 cells, because
overexpression of human E-cadherin in these cells attenuated
their invasiveness (Figure S5F). In intestinal tumors from
apcMin/+ mice lacking Abhd5, p53 and E-cadherin expression
levels were reduced and Snail expression was increased (Figure S5G). Collectively, these data demonstrate that Abhd5
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deficiency in HCT116 cells promotes EMT and cell invasion via
inhibiting p53 expression and function.
Abhd5 KD in HCT116 Cells Enhances Aerobic Glycolysis
To probe the metabolic and cellular basis for Abhd5 deficiencyinduced EMT, we examined the fat and glucose utilization. As expected, Abhd5 KD increased cellular content of triglycerides in
HCT116 cells (Figure 6A). Abhd5 deficiency is known to cause
intracellular lipid accumulation by inhibiting triglyceride catabolism instead of increasing triglyceride synthesis (Brown et al.,
2007; Guo et al., 2013; Lass et al., 2006; Radner et al., 2010).
We found that triglyceride hydrolase activity was reduced in
Abhd5-KD cell lysate (Figure 6B). While this was consistent
with a role of Abhd5 in promoting ATGL’s activity (Lass et al.,
2006), ATGL-KD HCT116 cells displayed reduced invasion capacity, increased p53 protein, and unaltered Snail expression,
though a slight reduction in E-cadherin was observed (Figures
S6A and S6B). Their growth was substantially attenuated (Figure S6C). In human CRC specimens, immunostaining did not
show any changes in ATGL expression levels between normal
colon mucosa and CRC tissues (Figure S6D). These data
demonstrate that ATGL deficiency does not increase, or correlate with, malignant properties of CRCs. Abhd5 must have
ATGL-independent functions, which, together with its ATGL coactivator function, ultimately determine the biological behavior of
cancer cells. One such function may be its role in activating macroautophagy, a cellular process that is critically involved in the
pathogenesis of cancer (Levine and Kroemer, 2008; White and
DiPaola, 2009). The microtubule-associated protein 1 light chain
3b-II (LC3b-II) is a lipidated form of LC3b-I and a reliable marker
for the state of autophagy (Klionsky et al., 2012). We found that
Abhd5-KD cells showed decreased, but ATGL-KD cells displayed increased, LC3b-II protein levels under normal culture
conditions (Figure 6C), though both cells exhibited reduced
LC3B-II protein levels when cultured in the serum-free medium,
a condition that is useful in examining the potential role of a protein in autophagy induction but is absent physiologically. Clearly,
lots of studies are required to address potential roles of Abhd5
and ATGL in regulating autophagy and perhaps lipophagy in
the future.
To determine how Abhd5 deficiency affects cell metabolism,
we first measured fatty acid oxidation potential of Abhd5-KD
HCT116 cells, because Abhd5-KD hepatoma cells have reduced
fatty acid oxidation (Brown et al., 2007). Consistently, CO2 production from [14C]palmitic acid was significantly decreased in
Abhd5-KD HCT116 cells (Figure 6D). Given that mitochondria
are the major sites of fatty acid, we analyzed mitochondrial functions in our cells by Seahorse studies. Abhd5-KD HCT116 cells
exhibited a significant reduction in both basal mitochondrial
oxygen consumption rates and mitochondrial oxidative capacity
(Figure 6E). MitoTracker Red staining revealed a dramatic
reduction in mitochondria in Abhd5-KD cells under both basal
and interleukin-4-stimulated conditions (Figure 6F), indicating
impaired mitochondrial biogenesis.
Impairment of mitochondrial functions may cause the Warburg
effect in cancer cells (Warburg, 1956). We have previously shown
that Abhd5 KD in mice promotes glucose disposal while inhibiting fat utilization (Brown et al., 2010). Consistently, glucose

transporter-1 (GLUT-1), glucose uptake under both basal and insulin-stimulated states, and lactate production were significantly
increased in Abhd5-KD HCT116 cells (Figures 6G and 6H); so did
protein levels of glycolytic enzymes, including hexokinase I
(HK-I), hexokinase II (HK-II), lactate dehydrogenase A (LDHA),
and pyruvate kinase muscle isozyme I (PK-M1) (Figure 6I).
Similar changes were also seen in Abhd5-KD SW620 cells,
except HK II, whose expression was unaltered (Figure S7A).
Additionally, expression levels of GLUT-1, HK-II, and LDHA
were increased in the intestinal tumor from apcMin/+ mice lacking
intestinal Abhd5 (Figure S7B). Cell apoptosis assays showed
that Abhd5-KD versus control HCT116 cells were more sensitive
to 3-bromopyruvatic acid (3-BrPA), a glycolysis inhibitor (Figure 6J). Very impressively, 3-BrPA or cytochalasin B (a glucose
transport inhibitor) reversed the effects of Abhd5 KD on EMT
in HCT116 cells (Figures 6K and 6L). These results suggest
that Abhd5 may act as a molecular switch of fuel selection, the
loss of which turns off mitochondrial fat oxidation and turns on
aerobic glycolysis (the Warburg effect).
Reduced AMPK Phosphorylation Mediates p53
Suppression and EMT in Abhd5-KD Colorectal
Cancer Cells
To determine whether altered fuel metabolism influences a cell’s
energy balance, we measured the cellular content of AMP and
ATP. The ratio of AMP to ATP was significantly reduced in
Abhd5-KD HCT116 cells (Figure 7A). Treatment with cytochalasin B or 3-BrPA completely prevented this reduction (Figure 7B), indicating that enhanced glucose uptake and glycolysis
were responsible for the reduced AMP:ATP ratio. AMPK is an energy sensor (Hardie, 2007). When cellular energy is abundant
(AMP decreases while ATP increases), AMPK phosphorylation
is suppressed to stimulate anabolic pathways. Consistent with
the decreased AMP:ATP ratio, phosphorylation of AMPKa was
substantially decreased in Abhd5-KD HCT116 cells (Figure 7C)
and SW620 cells (Figure S7A), but not in ATGL-KD HCT116 cells
(Figure S7C). It has been reported that glucose deprivation activates AMPK activity (Yun et al., 2005). To determine whether
reduced AMPK phosphorylation in Abhd5-KD cells resulted
from augmented glucose uptake and glycolysis, we treated our
cells with cytochalasin B (a glucose uptake inhibitor) or 3-BrPA
(a glycolysis inhibitor). Indeed, inhibiting glucose uptake or
glycolysis almost completely rescued AMPKa phosphorylation
in Abhd5-KD HCT116 cells (Figure 7C).
It has been shown that AMPK activation induces p53 phosphorylation on serine 15, which stimulates the transcriptional activity of p53 (Jones et al., 2005). Recently, AMPK was shown to
function as a negative regulator of the Warburg effect to suppress tumor growth (Faubert et al., 2013). Given that Abhd5-deficient HCT116 cells shifted their fuel metabolism to aerobic
glycolysis (Figure 6) and displayed loss of p53 phosphorylation
on serine 15 (Figure 5A), we hypothesized that inhibition of
AMPK phosphorylation may mediate suppression of p53 activity,
thereby inducing EMT in HCT116 cells. In agreement, cytochalasin B or 3-BrPA treatment that rescued AMPKa phosphorylation also rescued p53 expression in these cells (Figure 7C).
Importantly, constitutive activation of AMPKa in Abhd5-KD
HCT116 cells normalized expression levels of p53 and EMT
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Figure 6. Abhd5 Deficiency-Induced EMT in CRC Cells Depends on Glucose Uptake and Aerobic Glycolysis
(A) Triglyceride content of control and Abhd5-KD HCT116 cells.
(B) Triglyceride hydrolase activity of HCT116 cell lysates.
(C) Western blots of LC3b protein in HCT116 cells cultured in normal medium or serum-starved for 12 hr.
(D) CO2 produced from [14C]palmitic acid in HCT116 cells (n = 4). *p < 0.01.
(E) Seahorse Assays of mitochondrial oxygen consumption rates (OCRs) in HCT116 cells (n = 3). *p < 0.01.
(F) Mitochondria stained with MitoTracker Red FM in HCT116 cells. Scale bar represents 10 mm.
(G) GLUT1 protein expression as well as basal and insulin-stimulated uptake of [3H]2-deoxy-D-glucose in HCT116 cells (n = 3). *p < 0.05. **p < 0.01.
(H) Lactate concentrations in the lysate and culture medium of HCT116 cells (n = 3). *p < 0.05. **p < 0.01.
(I) Western blots of glycolytic proteins in HCT116 cells.

(legend continued on next page)

1806 Cell Reports 9, 1798–1811, December 11, 2014 ª2014 The Authors

Figure 7. Aerobic Glycolysis Induces p53 Suppression via Inactivating AMPK in Abhd5-Deficient Cells
(A) The AMP/ATP ratio in HCT116 cells.
(B) The AMP/ATP ratio in HCT116 cells treated with cytochalasin B (20 mM, 12 hr) or 3-BrPA (5 mg/ml, 12 hr).
(C) Western blots of p53 and phosphorylated (p)-AMPKa proteins in HCT116 cells treated with cytochalasin B (20 mM, 24 hr) and 3-BrPA (5 mg/ml, 24 hr).
(D) Western blots of p53, Snail, E-cadherin, and phosphorylated (p)-AMPKa proteins in HCT116 cells expressing constitutively active (CA) AMPKa1.
(E) Transwell assays of HCT116 cells expressing CA-AMPKa1.
(F) Western blots of HCT116 cells expressing a dominant-negative (DN) AMPKa1 (DNa1) or AMPKa2 (DNa2).
(G) Transwell assays of HCT116 cells expressing DNa1 or DNa2.
(H) Western blots of HCT116 cells expressing CA-AMPKa1 in the presence of Nutlin-3 (10 mM, 24 hr).
(I) Transwell assays of HCT116 cells expressing CA-AMPKa1 in the presence of Nutlin-3 (10 mM, 48 hr).
(J) Western blots of mTOR pathway proteins in HCT116 cells.
(K) Western blots of HCT116 cells treated with or without wortmannin (100 nmol/l for 24 hr).
(L) Proposed mechanisms underlying Abhd5 deficiency-induced malignancy in CRCs.
*p < 0.05; **p < 0.001; ***p < 0.0001.

markers (Figure 7D) and inhibited the cells’ invasive capacity
(Figure 7E). The opposite effects were observed when the dominant-negative form of AMPKa1 or AMPKa2 was introduced to
these cells (Figures 7F and 7G). In addition, Nutlin-3, an activator

of p53 activity, rescued the dominant-negative AMPKa-induced
changes in p53 and EMT markers (Figure 7H) as well as the invasive capacity (Figure 7I) of HCT116 cells. These findings together
indicate that AMPK functions as an upstream regulator of p53 to

(J) Flow cytometry analysis of apoptosis of HCT116 cells treated with a glycolysis inhibitor 3-bromopyruvate (BrPA).
(K) Western blots of EMT markers in Abhd5-KD HCT116 cells treated with a glycolysis inhibitor 3-BrPA (5 mg/ml, 24 hr) or a glucose transport inhibitor cytochalasin
B (20 mM, 24 hr).
(L) Transwell assays of Abhd5-KD HCT116 cells treated with 3-BrPA (5 mg/ml, 48 hr) or cytochalasin B (20 mM, 48 hr). Scale bar represents 100 mm.
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control the energy shift-induced EMT in Abhd5-KD HCT116
cells.
Studies have linked AMPK to the mTOR pathway (Lee et al.,
2007). In Abhd5-KD HCT116 cells, mTOR phosphorylation
(serine 2481), GbL, rictor, raptor, p70S6 kinase (85 kDa) phosphorylation (threonine 389), and eukaryotic initiation factor-4Ebinding protein-1 (4E-BP1) phosphorylation (threonine 37/46)
were all increased, though total mTOR and mTOR phosphorylation at serine 2448 remained unchanged (Figure 7J). This finding
indicates that the mTOR pathway is activated in these cells.
Given that mTOR mediates growth signals originated from activation of the PI3K-Akt pathway, we examined the effects of
Abhd5 KD on Akt phosphorylation in HCT116 cells. Akt phosphorylation at serine 473 was highly induced in Abhd5-KD cells
(Figure 7K). Inhibition of PI3K by wortmannin partially restored
expression levels of p53 and E-cadherin but failed to rescue
AMPK phosphorylation (Figure 7K), suggesting that Akt is upstream of p53, but downstream of AMPK, or in a pathway parallel
to the AMPK pathway. The PI3K-Akt and AMPK pathways
may converge and jointly regulate the p53-mTOR pathway (Figure 7L), as demonstrated previously (Feng et al., 2005; Jones
et al., 2005).
DISCUSSION
In this study, we demonstrate that Abhd5 (CGI-58), a lipolytic activator, is a tumor suppressor in colorectal cancer development
and progression. Our results from studies of cell behavior, genetically engineered animal models, and human patients strongly
support the following mechanisms (Figure 7K): Abhd5 acts as a
fuel switch whose deficiency inhibits mitochondrial fatty acid
oxidation (fat catabolism) and promotes glucose uptake and utilization. Due to defective fat catabolism, Abhd5-deficient cells
display severe mitochondrial dysfunction. Increased glucose is
channeled to aerobic glycolysis (the Warburg effect). Cells gain
more energy (reduced AMP:ATP ratio) due to increased glucose
influx that is likely promoted by activation of the PI3K/Akt
pathway. As a result, AMPK phosphorylation is suppressed.
Activation of the PI3K/Akt pathway and suppression of AMPK
phosphorylation inhibit p53 activity. Consequently, the mTOR
pathway is activated and autophagy is inhibited. Thus, Abhd5
deficiency-induced metabolic reprogramming activates a potent
oncogenic signaling network, at least in colorectal cancer cells.
Abhd5 was reported to promote triglyceride hydrolysis by activating ATGL’s triglyceride hydrolase activity in vitro (Lass et al.,
2006). However, we found no correlation between ATGL expression levels and malignant features in the human CRC samples
examined (Figure S6). This finding may not be surprising,
because mutations of Abhd5 and ATGL cause several distinct
phenotypes in both humans and mice (Fischer et al., 2007;
Haemmerle et al., 2006; Lefèvre et al., 2001; Radner et al.,
2010), suggesting that Abhd5 possesses ATGL-independent
functions. Perhaps Abhd5 has other lipase targets besides
ATGL. Alternatively, it may be unnecessary to reduce ATGL
expression to inhibit its activity, as downregulation of its coactivator Abhd5 may achieve the same goal. Interestingly, monoacylglycerol lipase (MAGL), the enzyme that cleaves the last
hydrocarbon chain on the glycerol backbone of triglyceride dur-

ing fat lipolysis, was shown to be upregulated in aggressive
human cancer cells and primary tumors, and promote tumor
aggressiveness (Nomura et al., 2010). While this study appears
to be contrary to ours and another report (Das et al., 2011),
because they showed that inhibition of a lipolytic enzyme prevents tumor development and progression, one should not
expect similar metabolic consequences of Abhd5 or ATGL mutations and MAGL deficiency. Their substrates are different. Abhd5
and ATGL are responsible for triglyceride breakdown. MAGL hydrolyzes monoacylglycerols. While the LDs induced by Abhd5 or
ATGL mutations may sequester oncogenic lipids inside the cell,
MAGL mutations reduce free fatty acids and their metabolites
(Nomura et al., 2010).
Aerobic glycolysis is a hallmark of cancer cell metabolism
(Warburg, 1956), but molecular mediators of this metabolic
rewiring are poorly understood. Many oncogenic proteins and
tumor suppressors may regulate carcinogenesis through their
regulatory roles in bioenergetics/metabolic pathways (Vogelstein and Kinzler, 2004). Here, we demonstrate that Abhd5
deficiency exacerbates the Warburg effect by inhibiting fat
catabolism. Metabolic rewiring often shifts energy balance in a
cell. For a glucose molecule, the energy (quantity of ATP) produced from aerobic glycolysis is substantially lower than that
from mitochondrial oxidative phosphorylation. However, when
the flux rate of glucose through the pathway is much faster,
glycolysis relative to oxidative phosphorylation has the potential
to produce more ATP (Guppy et al., 1993). Consistently, Abhd5deficient cancer cells display a positive energy balance as evidenced by a decreased AMP:ATP ratio, despite their preferential
use of aerobic glycolysis as an energy source. This energy surplus is sensed by AMPK. AMPK was recently shown to function
as a negative regulator of the Warburg effect to suppress tumor
growth (Faubert et al., 2013), which is totally consistent with our
current findings.
It has been shown that glucose deprivation-induced AMPK
activation enhances p53 functions by increasing total p53
protein, p53 phosphorylation at serine 15, and p53-dependent
transcription (Jones et al., 2005). The activation of p53 by
AMPK likely suppresses glycolysis to restore the cell’s energy
balance by promoting catabolism (Jones and Thompson,
2009; Kruse and Gu, 2006). Our results are in agreement with
these early studies. Considering that Abhd5-deficient cells are
bioenergetically forced to ferment glucose for energy production, it appears that Abhd5 deficiency creates a futile cycle
to worsen aerobic glycolysis via suppressing the AMPK-p53
pathway. This futile cycle may explain why Abhd5 deficiency
alone is able and sufficient to induce malignant transformation
of normal fibroblasts in culture and a xenograft model (Figure 2)
and to further enhance the aggressiveness of HCT116 cancer
cells whose baseline aerobic glycolysis level is already high.
An important finding from our studies is the key role of Abhd5
in limiting EMT of colorectal cancer cells. EMT is critically
involved in tumor metastasis (Chaffer and Weinberg, 2011).
Consistently, we showed that Abhd5 deficiency in HCT116 cells
enhances a cell’s invasiveness in Matrigel assays and a growth
advantage in the lungs of nude mice. Our data collectively support that EMT induction in Abhd5-deficient cells is a direct result
of the suppression of the AMPK-p53 pathway. Thus, we have
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identified Abhd5 as a factor that links fuel metabolism to EMT
through the AMPK-p53 pathway.
ApcMin/+ mice develop adenomatous polyps due to Wnt
pathway activation (Behrens et al., 1998; Rubinfeld et al.,
1993). Normally, these polyps are located mainly in the distal
segment of the small intestine and rarely seen in colorectum
(Su et al., 1992). All Abhd5-deficient ApcMin/+ mice were found
to bear significantly increased tumors of large size in colon and
rectum, highlighting a strong tumor-suppression role of Abhd5
in colorectal carcinogenesis. This role of Abhd5 does not seem
to be mediated by b-catenin, c-myc, Ras, or PTEN, because
none of these oncogenic proteins are elevated in Abhd5-KD
cells. Our in vivo and in vitro observations instead demonstrate
that Abhd5 itself is a tumor suppressor and its loss directly
causes malignant transformation. This tumor-suppressor role
of Abhd5 likely contributes to the strong negative correlation between Abhd5 expression levels and CRC malignant properties in
human CRC tissues. Colorectal tumor cells may choose to
downregulate Abhd5 to promote the Warburg effect, thereby
enhancing their malignancy. The downregulation of Abhd5 may
partly explain the epidemic of cytosolic LD deposition seen in human colorectal and other cancers (Accioly et al., 2008; Straub
et al., 2010) because a hallmark of Abhd5 deficiency is the cytosolic LD accumulation. Our findings raise an intriguing question:
How is Abhd5 expression downregulated in human malignant tumors? Is it at the epigenetic, transcriptional, posttranscriptional,
and/or posttranslational level? Is Abhd5 genetically mutated?
Although the loss of copy number and heterozygosity of Abhd5
gene are seen in many cancers, including CRCs (COSMIC database), which supports Abhd5 as a tumor suppressor, extensive
genetic and epigenetic screening of Abhd5 gene sequences in
a large panel of human tumors is warranted. We did not see
any differences in Abhd5 expression among normal colon mucosa, colitis, and colon hyperplasia, but we did observe a partial
loss of Abhd5 expression in adenomas and an extensive loss
in CRCs, implying that Abhd5 deficiency may be implicated in
adenoma development and, importantly, in malignant transformation of adenomas to CRCs.
In summary, genetic inactivation of Abhd5 in normal cells and
APCMin/+ mice facilitates tumorigenesis and malignant transformation. Silencing of Abhd5 in colorectal cancer cells inhibits fatty
acid oxidation and enhances glucose uptake and aerobic glycolysis. This metabolic reprogramming promotes carcinogenesis
and EMT-driven malignancy by activating the PI3K/Akt pathway and suppressing the AMPK-p53 pathway. Loss of Abhd5
expression occurs frequently in human colorectal carcinomas
and is strongly associated with malignant properties. These results strongly argue for Abhd5 as a colorectal tumor suppressor
whose expression level may serve as a biomarker for assessing
the malignant transformation risk of the tumor.

mice to produce ApcMin/+ mice lacking Abhd5 in the intestine and their control
littermates for experiments. The Institutional Animal Care and Use Committee
at the University of Maryland approved all animal procedures.
Cells
All human colorectal colon cancer cell lines, the FHC human normal colon
mucosal cell line, and the BJ human fibroblast cell line were purchased from
ATCC. The p53-null HCT116 cell line and its parental HCT116 cell line were
obtained from Dr. Bert Vogelstein’s lab at the Johns Hopkins University School
of Medicine.
Human Samples
Tissue chips and biopsy specimens were used. The tumors were staged by three
anatomic pathologists blinded to the patient information, in the Department of
Pathology, Southwest Hospital, according to the Union for International Cancer
Control classification system. The Ethics Committee of Southwest Hospital, the
Third Military Medical University, approved all human experiments.
Packaging and Transfection of Lentiviruses
Human Abhd5 and ATGL shRNA constructs for lentivirus packaging were purchased from Open Biosystems and OriGene. The following sequences were
used to silence Abhd5 expression in human cells: 50 -AAGATCACTGAAACTGG
AATG-30 , 50 -TCTTTGCACCAACAGACCTGTCTATGCTT-30 (TL306992A), and
50 -AGACGATACTGTGACAGAATACATCTACC-30 (TL306992C). The following
sequence was used to silence ATGL expression in human cells: 50 -AAGTGGG
ATATAATGACATTC-30 .
Plasmids and Transfection
Construction of constitutively active and dominant-negative a1 and a2 AMPK
expression vectors was described previously (Stein et al., 2000). The expression plasmid of human p53 (#SC119832) and the control empty vector
pCMV6-XL5 were purchased from OriGene.
Antibodies, Immunohistochemistry, Immunofluorescence, Oil Red O
Staining, Protein Extraction, Western Blotting, Preparation of
Nuclear Extracts, and Quantitative Real-Time PCR
Routine methods were used in these experiments.
Flow Cytometry of Apoptosis
Cell apoptosis was assessed by flow cytometry of Annexin V/PI (SigmaAldrich) staining.
Transwell Assay
The migration ability of cells was assessed using Transwell chambers with
polycarbonate membrane filters with 24-well inserts (6.5 mm diameter and
8 mm pore size; Corning Life Sciences). The membrane filters were coated
with 1.5 mg/ml Matrigel (BD Biosciences) before use.
Lipase Activity Assay
The lipase activity of cells was assessed using the fluorogenic ester substrate
4-methylumbelliferyl heptanoate (Sigma-Aldrich).
Deoxyglucose Uptake and Lactate Assays
Glucose uptake of cells was assayed using [3H]-2-deoxy-D-glucose as a tracer
in the absence and presence of cytochalasin B. Lactate production was
measured using a commercial assay kit.
Fatty Acid Oxidation Assay
[14C]Palmitic acid was used as the substrate in the assay.

EXPERIMENTAL PROCEDURES
Creation of ApcMin/+ Mice Lacking Intestinal Abhd5
Intestine-specific Abhd5 knockout mice (Xie et al., 2014) were generated by mating Abhd5-floxed mice created in our lab (Guo et al., 2013) with B6.SJL-Tg (Vilcre)977Gum/J mice (Jackson Laboratory, stock #004586). A male ApcMin/+
mouse on the C57BL/6J background was purchased from The Jackson Laboratory (stock #002020) and crossed with female intestine-specific Abhd5 knockout

Seahorse Assays for Mitochondria Functions
Cell mitochondrial oxygen consumption rates were assayed in 96-well plates
by using a XF Cell Mito Stress Test Kit on the XFe96 Extracellular Flux Analyzer.
Staining of Mitochondria
Cells were stained with MitoTracker Red FM in the absence or presence of
interleukin-4.
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Intracellular Contents of AMP and ATP
Cells were extracted by perchloric acid and the lysate was analyzed by highpressure liquid chromatography on a Waters C18 column using a Waters 2695
separations module and a 2487 dual-absorbance detector.
Tumor Counting and Size Measurement in Mice
Fixed intestines were stained with methylene blue. The location and size of
each tumor were recorded and analyzed by ImageJ Software (NIH).
Ectopic Growth Model
Four- to 6-week-old BALB/c nude female mice were purchased from the
National Cancer Institute/NIH (Fredrick, MD). The metastatic ability of cells
was assessed by tail vein injection of cells. Animals were sacrificed 8 weeks
after injection and tissues examined for cancer cell lesions.
Subcutaneous Xenograft Models
Four- to 6-week-old BALB/c nude mice were purchased from the Experimental Animal Center, the Institute of Laboratory Animal Sciences (China).
The mice were subcutaneously injected with BJ cells at the thighs. The mice
were examined weekly and sacrificed 8 weeks after injection for xenograft
collection.
Statistical Analysis
Data are expressed as mean ± SEM. For more details on each method and
statistical analysis, please see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2014.11.016.
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